Cargando…

Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy

BACKGROUND: Although the prognostic biomarkers associated with colorectal cancer (CRC) survival are well known, there are limited data on the association between the molecular characteristics and survival after recurrence (SAR). The purpose of this study was to assess the association between pathway...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Dae-Won, Han, Sae-Won, Cha, Yongjun, Bae, Jeong Mo, Kim, Hwang-Phill, Lyu, Jaemyun, Han, Hyojun, Kim, Hyoki, Jang, Hoon, Bang, Duhee, Won, Jae-Kyung, Jeong, Seung-Yong, Park, Kyu Joo, Kang, Gyeong Hoon, Kim, Tae-You
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501409/
https://www.ncbi.nlm.nih.gov/pubmed/31060539
http://dx.doi.org/10.1186/s12885-019-5650-0
_version_ 1783416108720586752
author Lee, Dae-Won
Han, Sae-Won
Cha, Yongjun
Bae, Jeong Mo
Kim, Hwang-Phill
Lyu, Jaemyun
Han, Hyojun
Kim, Hyoki
Jang, Hoon
Bang, Duhee
Won, Jae-Kyung
Jeong, Seung-Yong
Park, Kyu Joo
Kang, Gyeong Hoon
Kim, Tae-You
author_facet Lee, Dae-Won
Han, Sae-Won
Cha, Yongjun
Bae, Jeong Mo
Kim, Hwang-Phill
Lyu, Jaemyun
Han, Hyojun
Kim, Hyoki
Jang, Hoon
Bang, Duhee
Won, Jae-Kyung
Jeong, Seung-Yong
Park, Kyu Joo
Kang, Gyeong Hoon
Kim, Tae-You
author_sort Lee, Dae-Won
collection PubMed
description BACKGROUND: Although the prognostic biomarkers associated with colorectal cancer (CRC) survival are well known, there are limited data on the association between the molecular characteristics and survival after recurrence (SAR). The purpose of this study was to assess the association between pathway mutations and SAR. METHODS: Of the 516 patients with stage III or high risk stage II CRC patients treated with surgery and adjuvant chemotherapy, 87 who had distant recurrence were included in the present study. We analyzed the association between SAR and mutations of 40 genes included in the five critical pathways of CRC (WNT, P53, RTK-RAS, TGF-β, and PI3K). RESULTS: Mutation of genes within the WNT, P53, RTK-RAS, TGF-β, and PI3K pathways were shown in 69(79.3%), 60(69.0%), 57(65.5%), 21(24.1%), and 19(21.8%) patients, respectively. Patients with TGF-β pathway mutation were younger and had higher incidence of mucinous adenocarcinoma (MAC) histology and microsatellite instability-high. TGF-β pathway mutation (median SAR of 21.6 vs. 44.4 months, p = 0.021) and MAC (20.0 vs. 44.4 months, p = 0.003) were associated with poor SAR, and receiving curative resection after recurrence was associated with favorable SAR (Not reached vs. 23.6 months, p <  0.001). Mutations in genes within other critical pathways were not associated with SAR. When MAC was excluded as a covariate, multivariate analysis revealed TGF-β pathway mutation and curative resection after distant recurrence as an independent prognostic factor for SAR. The impact of TGF-β pathway mutations were predicted using the PROVEAN, SIFT, and PolyPhen-2. Among 25 mutations, 23(92.0%)-24(96.0%) mutations were predicted to be damaging mutation. CONCLUSIONS: Mutation in genes within TGF-β pathway may have negative prognostic role for SAR in CRC. Other pathway mutations were not associated with SAR. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5650-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6501409
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65014092019-05-10 Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy Lee, Dae-Won Han, Sae-Won Cha, Yongjun Bae, Jeong Mo Kim, Hwang-Phill Lyu, Jaemyun Han, Hyojun Kim, Hyoki Jang, Hoon Bang, Duhee Won, Jae-Kyung Jeong, Seung-Yong Park, Kyu Joo Kang, Gyeong Hoon Kim, Tae-You BMC Cancer Research Article BACKGROUND: Although the prognostic biomarkers associated with colorectal cancer (CRC) survival are well known, there are limited data on the association between the molecular characteristics and survival after recurrence (SAR). The purpose of this study was to assess the association between pathway mutations and SAR. METHODS: Of the 516 patients with stage III or high risk stage II CRC patients treated with surgery and adjuvant chemotherapy, 87 who had distant recurrence were included in the present study. We analyzed the association between SAR and mutations of 40 genes included in the five critical pathways of CRC (WNT, P53, RTK-RAS, TGF-β, and PI3K). RESULTS: Mutation of genes within the WNT, P53, RTK-RAS, TGF-β, and PI3K pathways were shown in 69(79.3%), 60(69.0%), 57(65.5%), 21(24.1%), and 19(21.8%) patients, respectively. Patients with TGF-β pathway mutation were younger and had higher incidence of mucinous adenocarcinoma (MAC) histology and microsatellite instability-high. TGF-β pathway mutation (median SAR of 21.6 vs. 44.4 months, p = 0.021) and MAC (20.0 vs. 44.4 months, p = 0.003) were associated with poor SAR, and receiving curative resection after recurrence was associated with favorable SAR (Not reached vs. 23.6 months, p <  0.001). Mutations in genes within other critical pathways were not associated with SAR. When MAC was excluded as a covariate, multivariate analysis revealed TGF-β pathway mutation and curative resection after distant recurrence as an independent prognostic factor for SAR. The impact of TGF-β pathway mutations were predicted using the PROVEAN, SIFT, and PolyPhen-2. Among 25 mutations, 23(92.0%)-24(96.0%) mutations were predicted to be damaging mutation. CONCLUSIONS: Mutation in genes within TGF-β pathway may have negative prognostic role for SAR in CRC. Other pathway mutations were not associated with SAR. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5650-0) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-06 /pmc/articles/PMC6501409/ /pubmed/31060539 http://dx.doi.org/10.1186/s12885-019-5650-0 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Lee, Dae-Won
Han, Sae-Won
Cha, Yongjun
Bae, Jeong Mo
Kim, Hwang-Phill
Lyu, Jaemyun
Han, Hyojun
Kim, Hyoki
Jang, Hoon
Bang, Duhee
Won, Jae-Kyung
Jeong, Seung-Yong
Park, Kyu Joo
Kang, Gyeong Hoon
Kim, Tae-You
Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy
title Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy
title_full Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy
title_fullStr Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy
title_full_unstemmed Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy
title_short Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy
title_sort association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501409/
https://www.ncbi.nlm.nih.gov/pubmed/31060539
http://dx.doi.org/10.1186/s12885-019-5650-0
work_keys_str_mv AT leedaewon associationofpathwaymutationwithsurvivalafterrecurrenceincolorectalcancerpatientstreatedwithadjuvantfluoropyrimidineandoxaliplatinchemotherapy
AT hansaewon associationofpathwaymutationwithsurvivalafterrecurrenceincolorectalcancerpatientstreatedwithadjuvantfluoropyrimidineandoxaliplatinchemotherapy
AT chayongjun associationofpathwaymutationwithsurvivalafterrecurrenceincolorectalcancerpatientstreatedwithadjuvantfluoropyrimidineandoxaliplatinchemotherapy
AT baejeongmo associationofpathwaymutationwithsurvivalafterrecurrenceincolorectalcancerpatientstreatedwithadjuvantfluoropyrimidineandoxaliplatinchemotherapy
AT kimhwangphill associationofpathwaymutationwithsurvivalafterrecurrenceincolorectalcancerpatientstreatedwithadjuvantfluoropyrimidineandoxaliplatinchemotherapy
AT lyujaemyun associationofpathwaymutationwithsurvivalafterrecurrenceincolorectalcancerpatientstreatedwithadjuvantfluoropyrimidineandoxaliplatinchemotherapy
AT hanhyojun associationofpathwaymutationwithsurvivalafterrecurrenceincolorectalcancerpatientstreatedwithadjuvantfluoropyrimidineandoxaliplatinchemotherapy
AT kimhyoki associationofpathwaymutationwithsurvivalafterrecurrenceincolorectalcancerpatientstreatedwithadjuvantfluoropyrimidineandoxaliplatinchemotherapy
AT janghoon associationofpathwaymutationwithsurvivalafterrecurrenceincolorectalcancerpatientstreatedwithadjuvantfluoropyrimidineandoxaliplatinchemotherapy
AT bangduhee associationofpathwaymutationwithsurvivalafterrecurrenceincolorectalcancerpatientstreatedwithadjuvantfluoropyrimidineandoxaliplatinchemotherapy
AT wonjaekyung associationofpathwaymutationwithsurvivalafterrecurrenceincolorectalcancerpatientstreatedwithadjuvantfluoropyrimidineandoxaliplatinchemotherapy
AT jeongseungyong associationofpathwaymutationwithsurvivalafterrecurrenceincolorectalcancerpatientstreatedwithadjuvantfluoropyrimidineandoxaliplatinchemotherapy
AT parkkyujoo associationofpathwaymutationwithsurvivalafterrecurrenceincolorectalcancerpatientstreatedwithadjuvantfluoropyrimidineandoxaliplatinchemotherapy
AT kanggyeonghoon associationofpathwaymutationwithsurvivalafterrecurrenceincolorectalcancerpatientstreatedwithadjuvantfluoropyrimidineandoxaliplatinchemotherapy
AT kimtaeyou associationofpathwaymutationwithsurvivalafterrecurrenceincolorectalcancerpatientstreatedwithadjuvantfluoropyrimidineandoxaliplatinchemotherapy